Glaxo Raises Human Genome Bid to $14 a Share, Reuters Says

GlaxoSmithKline Plc raised its hostile takeover offer for Human Genome Sciences Inc. to about $14 a share, Reuters reported, citing two people familiar with the situation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.